Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Aging (Albany NY). 2009 Mar 28;1(3):281-8.

Validation of anti-aging drugs by treating age-related diseases.

Author information

  • Cancer Center, Ordway Research Institute, Albany, NY 12208, USA.

Abstract

Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

KEYWORDS:

anti-aging drugs; atherosclerosis; cancer; diseases; metformin; rapamycin; resveratrol

PMID:
20157517
[PubMed - indexed for MEDLINE]
PMCID:
PMC2806014
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1.
Figure 2.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Impact Journals, LLC Icon for PubMed Central
    Loading ...
    Write to the Help Desk